ATRA, a vitamin A derivative approved for in vivo use, has proven effective in enhancing CD38 levels in several ex vivo myeloma cell preparations, leading to improved efficacy of therapeutic antibodies (8). This evidence concerns the gene CD38 and plasma cell myeloma.